The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers-Reference-Cited by-同舟云学术

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers

Published:2018-10-18 Issue:10 Volume:13 Page:e0206007
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lamarca Angela^ORCID,Galdy Salvatore,Barriuso Jorge,Moghadam Sharzad,Beckett Elizabeth,Rogan Jane,Backen Alison,Billington Catherine,McNamara Mairéad G.,Hubner Richard A.,Cramer Angela,Valle Juan W.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference60 articles.

1. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution;M. L. DeOliveira;Ann Surg

2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;J. Valle;N.Engl.J.Med

3. Second-line chemotherapy in advanced biliary cancer: a systematic review;A. Lamarca;Ann.Oncol

4. ABC-06: A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy for patients with locally advanced / metastatic biliary tract cancer (ABC) previously treated with cisplatin / gemcitabine chemotherapy;A. Lamarca;Ann Oncol,2014

5. New Horizons for Precision Medicine in Biliary Tract Cancers;J. W. Valle;Cancer Discov

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

2. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives;European Journal of Cancer;2024-03

3. Nrf2 and Her3 co-expression in cholangiocarcinoma: Possible biological pathways for potential therapeutic approach;Hepatobiliary & Pancreatic Diseases International;2023-02

4. Molecular diagnostics and biomarkers in cholangiocarcinoma;Surgical Oncology;2022-09

5. Molecular-driven treatment for biliary tract cancer: the promising turning point;Expert Review of Anticancer Therapy;2021-09-24